Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Affiliation

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: [Email]

Abstract

Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker.

Keywords

combined positive score,immunotherapy,ovarian cancer,pembrolizumab,